Where The Buying Ran Strongest: 24 Small Cap Stocks At 52-Week Highs
Strength in small caps is showing up in specific sectors, but not all new highs are built on the same foundation.
Biotechnology leads the charge today, with 8 names on a list of 24 Small Cap stocks at new 52-week highs. The largest is Nuvalent (NUVL), with a market value of about $9.7 billion, which has gained 36.1% in the last month alone. That run is not an outlier; Mirum Pharmaceuticals (MIRM) is up 37.5% over the same period, while the S&P 500 returned +1.1%.
The central question is what kind of business performance is driving these prices. Below are the names hitting their strongest levels of the past year.
The Complete 52-Week-High List
- 1 S&P 500 Stock Just Touched 52-Week Lows
- The 52-Week-Low List: 29 Names On Thursday
- The 52-Week-High List: 6 S&P 500 Names On Thursday
- Large Cap Stocks At 52-Week Highs: Thursday’s Full List
- S&P 500 Movers | Winners: AKAM, ANET, SMCI | Losers: SYF, MRNA, SW
- Market Movers | Winners: VTAK, TVRD, FRTT | Losers: ONFO, CLRO, BTAI
The table below shows the 10 largest of the 24 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| NUVL | $9.7 Bil | 0.0% | 0.2% | 36.1% | 58.9% |
| GKOS | $8.9 Bil | 1.5% | 9.4% | 22.4% | 50.8% |
| FR | $8.6 Bil | 0.3% | 5.4% | 5.8% | 37.2% |
| IMVT | $8.2 Bil | 0.5% | 4.6% | 29.6% | 145.5% |
| SGHC | $7.9 Bil | 4.4% | 14.5% | 20.3% | 41.7% |
| MIRM | $7.6 Bil | 0.2% | 9.8% | 37.5% | 154.7% |
| ACA | $7.1 Bil | 0.4% | 0.1% | 18.7% | 62.9% |
| MATX | $6.2 Bil | 3.1% | 6.5% | 9.3% | 87.6% |
| PBF | $6.2 Bil | 9.2% | 16.2% | 24.5% | 124.5% |
| XENE | $6.1 Bil | 10.4% | 15.9% | 35.2% | 119.8% |
Does the business performance justify the new price?
A look at the fundamentals reveals very different profiles. Glaukos (GKOS) saw its revenue grow 36.3% over the last twelve months, but its operating margin is -36.1%. In contrast, First Industrial Realty Trust (FR) has a positive operating margin of 41.2% on revenue growth of 8.8%. It trades at 25.0 times trailing earnings, a valuation that reflects its current profitability.
So what is the disciplined way to read this list?
A 52-week high is a sign of strength, and strong stocks often continue to perform. But a price is not a verdict on a company’s quality. The disciplined approach is to treat the list as a starting point. The work begins after reading the name: checking whether the underlying business fundamentals can support the new, higher valuation.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
One more pattern worth noticing: 10 of the 24 names are Health Care stocks. When a whole group is making new highs together, a biotech ETF like XBI is one way to own the group’s strength without betting on which single name leads it from here.
New Highs Fade. Discipline Compounds
Some of the names on this list will keep setting highs for years, and some are at the top of their run right now. Sorting one from the other, name by name, every day, is the work most investors never keep up with.
That sorting is what the Trefis High Quality (HQ) Portfolio does systematically: about 30 quality businesses screened for the fundamentals that sustain a run, held with rules instead of excitement. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Use the high list for ideas; use the portfolio for the compounding.